Avtor/Urednik		Skorjanec, S.; Kokot, A.; Drmić, Domagoj; Radic, B.; Sever, M.; Klicek, R.; Kolenc, Danijela; Zenko, A.; Lovric Bencic, M.; Belosic Halle, Z.
Naslov		Duodenocutaneous fistulainrats asa modelfor "wound healing-therapy" inulcer healing
Tip		članek
Vir		In: Book of abstracts of the 13th international conference on gastrointestinal research, 13th international conference ob ulcer research; 2009 Sep 10-16; Split Krakow : Polish physiological society
Vol. in št.		Letnik 66, št. 4
Leto izdaje		2015
Obseg		str. 581-590
ISSN		0867-5910 - Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Jezik		eng
Abstrakt		While very rarely reported, duodenocutanenous fistula research might alter the duodenal ulcer disease background andtherapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, ananti-ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L-arginine, and nitric oxide synthase-inhibitor L-nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, usingthe successful BPC 157, with nitric oxide-system involvement, the "wound healing-therapy", to heal the duodenal ulcer,the fistula-model that recently highlighted gastric and skin ulcer healing. Pressure in the lower esophageal and pyloricsphincters was simultaneously assessed. Duodenocutaneous fistula-rats received BPC 157 (10 microg/kg or 10 ng/kg,intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kgintraperitoneally) alone and/or together, throughout 21 days. Duodenocutaneous fistula-rats maintained persistentdefects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4thday, all fully counteracted in allBPC 157-rats. The BPC 157-rats experienced rapidly improved complete presentation (maximal volume instilledalready at 7thday). L-NAME further aggravated the duodenocutaneous fistula-course (mortality at 70% until the 4thday);L-arginine was beneficial (no mortality; however, maximal volume instilled not before 21th day). L-NAME-worseningwas counteracted to the control level with the L-arginine effect, and vice versa, while BPC 157 annulled the L-NAMEeffects (L-NAME + L-arginine; L-NAME + BPC157; L-NAME + L-arginine + BPC157 brought below the level of thecontrol). It is likely that duodenocutaneous fistulas, duodenal/skin defect simultaneous healing, reinstated sphincterfunction, are a new nitric oxide-system related phenomenon. In conclusion, resolving the duodenocutanenous fistulas-healing, nitric oxide-system involvement, should illustrate further wound healing therapy to heal duodenal ulcers.
Proste vsebinske oznake		L-arginine gastric pentadecapeptide duodenocutanenous fistula nitric oxide L-arginin želodčni pentadekapeptid duodenokutanenska fistula dušikov oksid